艾力曼·马合木提,Nicolas Meneveau,刘品明,Francois Schiele,Jean-Pierre Bassand

• 1:法国Besanon Franche-comté大学大学中心医院心脏中心
• 2:法国Besanon
• 3:Franche-comté大学大学中心医院心脏中心
• 4:中山医科大学第二附属医院心内科

摘要(Abstract)：

目的比较药物涂层支架(DES)与金属裸支架(BMS)置入前后冠状动脉循环内局部血浆组织因子(TF)水平的变化,探讨DES对血浆TF水平的早期改变及其对急性支架内血栓(AST)形成的意义。方法入选稳定型心绞痛患者26例,按标准方法行冠状动脉造影证实有冠状动脉狭窄均在70%以上。其中15例置入DES(DES组),11例置入BMS(BMS组)。全部患者术前给予阿司匹林、氯吡格雷口服,支架置入前静脉给予低分子质量肝素。PCI术中冠状动脉内血样采集顺序依次为:支架置入前后冠状动脉入口处(ostium)用引导导管,支架置入后15 min通过血栓吸引器穿过病灶在病灶下方(beyond the lesion)采血。血浆TF水平检测采用酶联免疫双抗体夹心法(ELISA)。结果PCI术前26例患者在冠状动脉入口处与病灶下方冠状动脉循环内的TF基线水平比较差异无统计学意义(31.50±7.05 ng/L比31.40±7.30 ng/L,P=0.748),但高于正常参考值3倍;支架置入后15min在冠状动脉入口处(29.60±6.96 ng/L比31.50±7.05 ng/L,P=0.135)与病灶下方(30.70±7.70 ng/L比31.40±6.30 ng/L,P=0.230)冠状动脉循环内的TF水平与术前比较,差异亦无统计学意义。术后15min,DES组和BMS组冠状动脉入口处(31.20±4.37 ng/L比30.70±5.39 ng/L,P=0.674)及病灶下方(31.60±5.39 ng/L比29.00±7.96 ng/L,P=0.789)TF水平差异均无统计学意义。结论稳定型心绞痛患者冠状动脉循环血内存在大量的TF。DES和BMS两种支架均不引起冠状动脉内局部、早期血浆TF水平的改变。

关键词(KeyWords)： 血管成形术,经腔,经皮冠状动脉;支架;冠状动脉血栓形成;组织因子

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 艾力曼·马合木提,Nicolas Meneveau,刘品明,Francois Schiele,Jean-Pierre Bassand

参考文献(References)：

• [1]Moreno R,Fernandez C,Hernandez R,et al.Drug-eluting stentthrombosis:results from a pooled analysis including 10 random-ized studies.J Am Coll Cardiol,2005,45:954-959.
• [2]Camenzind E,Steg PG,Wijns W.Safety of drug-eluting stents:a meta-analysis of1st generation DES programs.Abstract presen-ted at:World Congress of Cardiology 2006,September 2-6,2006,Barcelona,Spain.
• [3]Bavry AA,Kumbhani DJ,Helton TJ,et al.What is the risk ofstent thrombosis associated with the use of paclitaxel-elutingstents for percutaneous coronary intervention?A meta-analysis.JAm Coll Cardiol,2005,45:941-946.
• [4]Bavry AA,Kumbhani DJ,Helton TJ,et al.Risk of thrombosiswith the use of sirolimus-eluting stents for percutaneous coronaryintervention(from registry and clinical trial data).Am J Cardi-ol,2005,95:1469-1472.
• [5]Iakovou I,Schmidt T,Bonizzoni E,et al.Incidence,predic-tors,and outcome of thrombosis after successful implantation ofdrug-eluting stents.JAMA,2005,293:2126-2130.
• [6]Chieffo A,Bonizzoni E,Orlic D,et al.Intraprocedural stentthrombosis during implantation of sirolimus-eluting stents.Circu-lation,2004,109:2732-2736.
• [7]Alfonso F,Suarez A,Angiolillo DJ,et al.Findings of intravas-cular ultrasound during acute stent thrombosis.Heart,2004,90:1455-1459.
• [8]Regar E,Lemos PA,Saia F,et al.Incidence of thrombotic stentocclusion during the first three months after sirolimus-eluting stentimplantation in 500 consecutive patients.Am J Cardiol,2004,93:1271-1275.
• [9]Korovesis S,Fredericks S,Holt D,et al.Release of platelet ac-tivation markers during coronary angioplasty.Coron Artery Dis,2000,11:391-398.
• [10]Inoue T,Sohma R,Miyazaki T,et al.Comparison of activationprocess of platelets and neutrophils after coronary stent implanta-tion versus balloon angioplasty for stable angina pectoris.Am JCardiol,2000,86:1057-1062.
• [11]Steffel J,Latini RA,Akhmedov A,et al.Rapamycin,but notFK-506,increases endothelial tissue factor expression.Implica-tions for drug-eluting stent design.Circulation,2005,112:2002-2011.
• [12]Stahli BE,Camici GG,Steffel J,et al.Paclitaxel enhancesthrombin-induced endothelial tissue factor expression via c-Junterminal NH2 kinase activation.Circ Res,2006,99:149-155.
• [13]Alfonso F,Suarez A,Angiolillo DJ,et al.Findings of intravas-cular ultrasound during acute stent thrombosis.Heart,2004,90:1455-1459.
• [14]Cutlip DE,Baim DS,Ho KK,et al.Stent thrombosis in themodern era:a pooled analysis of multicenter coronary stent clini-cal trials.Circulation,2001,103:1967-1971.
• [15]Park DW,Park SW,Park KH,et al.Frequency of and risk fac-tors for stent thrombosis after drug-eluting stent implantation dur-ing long-term follow-up.Am J Cardiol,2006,98:352-356.
• [16]Nordmann AJ,Briel M,Bucher HC.Mortality in randomizedcontrolled trials comparing drug-eluting versus bare metal stentsin coronary artery disease:a meta-analysis.Eur Heart J,2006,27:2784-2814.
• [17]Babinska A,Markell MS,Salifu MO,et al.Enhancement of hu-man platelet aggregation and secretion induced by rapamycin.Nephrol Dial Transplant,1998,13:3153-3159.
• [18]Mizuno O,Ikeda U,Hojo Y,et al.Tissue factor expression incoronary circulation as a prognostic factor for late restenosis aftercoronary angioplasty.Cardiology,2001,95:84-89.
• [19]Tutar E,Ozcan M,Kilickap M,et al.Elevated whole-blood tis-sue factor procoagulant activity as a marker of restenosis after per-cutaneous transluminal coronary angioplasty and stent implanta-tion.Circulation,2003,108:1581-1584.
• [20]Agraou B,Corseaux D,McFadden EP,et al.Effects of coronaryangioplasty on monocyte tissue factor response in patients withstable or unstable angina.Thromb Res,1997,88:237-243.
• [21]Shammas NW,Cunningham MJ,Pomerantz RM,et al.Markersof hemostatic activation in affected coronary arteries during angio-plasty.Thromb Haemost,1994,72:672-675.
• [22]Gy ngy si M,StrehblowC,Sperker W,et al.Platelet activationand high tissue factor level predict acute stent thrombosis in pigcoronary arteries:prothrombogenic response of drug-eluting orbare stent implantation within the first 24 hours.Thromb Haem-ost,2006,96:202-209.
• [23]Thiruvikraman SV,Guha A,Roboz J,et al.In situ localizationof tissue factor in human atherosclerotic plaques by binding ofdigoxigenin-labeled factors VIIa and X.Lab Invest,1996,75:451-61.
• [24]Hatakeyama K,Asada Y,Marutsuka K,et al.Expression of tis-sue factor in the rabbit aorta after balloon injury.Atherosclerosis,1998,139:265-271.
• [25]Asada Y,Marutsuka K,Hatakeyama K,et al.The role of tissuefactor in the pathogenesis of thrombosis and atherosclerosis.JAtheroscler Thromb,1998,4:135-139.